Table 1 Baseline patient characteristics according to serum ALB level in primary AML patients
Variables | Total | Serum ALB | P-value | ||
|---|---|---|---|---|---|
Q1(< 34.6 g/L) | Q2 (34.6–38.5 g/L) | Q3 (≥38.6 g/L) | |||
Participants, n | 394 | 130 | 131 | 133 | |
Sex, n (%) | 0.054 | ||||
Male | 206 (52.3) | 79 (60.8) | 61 (46.6) | 66 (49.6) | |
Female | 188 (47.7) | 51 (39.2) | 70 (53.4) | 67 (50.4) | |
Age | 55.1 ± 17.3 | 60.8 ± 15.1 | 56.2 ± 15.7 | 48.5 ± 18.6 | < 0.001 |
ECOG performance-status score, n (%) | 0.165 | ||||
0–1 | 165 (41.9) | 46 (35.4) | 61 (46.6) | 58 (43.6) | |
2–3 | 229 (58.1) | 84 (64.6) | 70 (53.4) | 75 (56.4) | |
Pulmonary infection, n (%) | 0.087 | ||||
No | 165 (41.9) | 46 (35.4) | 64 (48.9) | 55 (41.4) | |
Yes | 229 (58.1) | 84 (64.6) | 67 (51.1) | 78 (58.6) | |
FAB subtype, n (%) | 0.104 | ||||
AML-M2 | 174 (44.2) | 48 (36.9) | 67 (51.1) | 59 (44.4) | |
AML-M4 | 54 (13.7) | 15 (11.5) | 16 (12.2) | 23 (17.3) | |
AML-M5 | 127 (32.2) | 54 (41.5) | 34 (26.0) | 39 (29.3) | |
Others | 39 (9.9) | 13 (10.0) | 14 (10.7) | 12 (9.0) | |
Genomic risk category, n (%) | 0.605 | ||||
Low | 53 (18.2) | 18 (21.4) | 14 (14.3) | 21 (19.1) | |
Medium | 135 (46.2) | 40 (47.6) | 44 (44.9) | 51 (46.4) | |
High | 104 (35.6) | 26 (31) | 40 (40.8) | 38 (34.5) | |
Chemotherapy, n (%) | 0.001 | ||||
No | 97 (24.6) | 41 (31.5) | 38 (29.0) | 18 (13.5) | |
Yes | 297 (75.4) | 89 (68.5) | 93 (71.0) | 115 (86.5) | |
Hb (g/L) | 68.6 ± 20.4 | 65.1 ± 17.6 | 69.4 ± 19.2 | 71.3 ± 23.6 | 0.042 |
Plt (× 109/L) | 38.5 (18.2, 70.0) | 40.5 (18.0, 68.5) | 42.0 (20.5, 78.5) | 35.0 (20.0, 68.0) | 0.777 |
INR | 1.2 ± 0.2 | 1.2 ± 0.2 | 1.1 ± 0.1 | 1.1 ± 0.3 | < 0.001 |
Fib (g/L) | 3.6 ± 1.4 | 3.7 ± 1.5 | 3.5 ± 1.4 | 3.4 ± 1.3 | 0.268 |
TBIL (umol/L) | 11.8 (8.4, 16.5) | 11.2 (7.5, 17.1) | 11.4 (8.3, 16.3) | 12.1 (9.1, 17.4) | 0.211 |
DBIL (umol/L) | 3.7 (2.6, 5.4) | 4.0 (2.6, 6.3) | 3.3 (2.7, 5.3) | 3.5 (2.6, 5.0) | 0.194 |
AST (U/L) | 23.1 (16.6, 35.0) | 24.0 (16.0, 37.0) | 22.0 (16.9, 37.0) | 24.0 (16.9, 30.0) | 0.509 |
ALT (U/L) | 17.9 (12.0, 29.5) | 18.4 (11.8, 31.0) | 17.8 (11.9, 31.0) | 16.9 (12.0, 27.0) | 0.689 |
Crea (umol/L) | 69.0 (56.2, 89.0) | 72.5 (59.0, 95.2) | 65.1 (54.5, 87.3) | 68.3 (57.2, 84.0) | 0.084 |
Glu (mmol/L) | 6.5 ± 2.2 | 6.8 ± 2.6 | 6.3 ± 2.0 | 6.4 ± 2.2 | 0.255 |
UA, (mmol/L) | 346.9 ± 160.2 | 353.2 ± 171.3 | 320.5 ± 147.4 | 366.4 ± 158.8 | 0.057 |
BM Blast (%) | 57.4 ± 22.2 | 58.5 ± 22.2 | 58.1 ± 22.8 | 55.7 ± 21.5 | 0.536 |
SF (ng/mL) | 660.8 (387.4, 1218.0) | 854.0 (557.1, 1476.0) | 569.1 (379.8, 1075.0) | 617.7 (294.6, 995.1) | < 0.001 |
Myo (ng/mL) | 20.0 (17.9, 34.1) | 25.4 (20.0, 47.2) | 20.0 (17.2, 29.8) | 20.0 (16.4, 25.1) | 0.001 |
ALB (g/L) | 36.4 ± 5.0 | 30.8 ± 2.8 | 36.5 ± 1.1 | 41.8 ± 2.5 | < 0.001 |
60-day mortality, n (%) | < 0.001 | ||||
No | 280 (71.1) | 74 (56.9) | 95 (72.5) | 111 (83.5) | |
Yes | 114 (28.9) | 56 (43.1) | 36 (27.5) | 22 (16.5) | |